Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The role of extracellular vesicle fusion with target cells in triggering systemic inflammation.
Papareddy P, Tapken I, Kroh K, Varma Bhongir RK, Rahman M, Baumgarten M, Cim EI, Györffy L, Smeds E, Neumann A, Veerla S, Olinder J, Thorlacus H, Ryden C, Bartakova E, Holub M, Herwald H. Papareddy P, et al. Among authors: veerla s. Nat Commun. 2024 Feb 7;15(1):1150. doi: 10.1038/s41467-024-45125-1. Nat Commun. 2024. PMID: 38326335 Free PMC article.
STC1 expression by cancer-associated fibroblasts drives metastasis of colorectal cancer.
Peña C, Céspedes MV, Lindh MB, Kiflemariam S, Mezheyeuski A, Edqvist PH, Hägglöf C, Birgisson H, Bojmar L, Jirström K, Sandström P, Olsson E, Veerla S, Gallardo A, Sjöblom T, Chang AC, Reddel RR, Mangues R, Augsten M, Ostman A. Peña C, et al. Among authors: veerla s. Cancer Res. 2013 Feb 15;73(4):1287-97. doi: 10.1158/0008-5472.CAN-12-1875. Epub 2012 Dec 14. Cancer Res. 2013. PMID: 23243022
Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial.
Kimbung S, Markholm I, Bjöhle J, Lekberg T, von Wachenfeldt A, Azavedo E, Saracco A, Hellström M, Veerla S, Paquet E, Bendahl PO, Fernö M, Bergh J, Loman N, Hatschek T, Hedenfalk I; PROMIX Trialists Group. Kimbung S, et al. Among authors: veerla s. Int J Cancer. 2018 Feb 1;142(3):618-628. doi: 10.1002/ijc.31070. Epub 2017 Oct 13. Int J Cancer. 2018. PMID: 28940389 Free PMC article. Clinical Trial.
Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome.
Lindgren D, Frigyesi A, Gudjonsson S, Sjödahl G, Hallden C, Chebil G, Veerla S, Ryden T, Månsson W, Liedberg F, Höglund M. Lindgren D, et al. Among authors: veerla s. Cancer Res. 2010 May 1;70(9):3463-72. doi: 10.1158/0008-5472.CAN-09-4213. Epub 2010 Apr 20. Cancer Res. 2010. PMID: 20406976 Free article.
A molecular taxonomy for urothelial carcinoma.
Sjödahl G, Lauss M, Lövgren K, Chebil G, Gudjonsson S, Veerla S, Patschan O, Aine M, Fernö M, Ringnér M, Månsson W, Liedberg F, Lindgren D, Höglund M. Sjödahl G, et al. Among authors: veerla s. Clin Cancer Res. 2012 Jun 15;18(12):3377-86. doi: 10.1158/1078-0432.CCR-12-0077-T. Epub 2012 May 2. Clin Cancer Res. 2012. PMID: 22553347 Free article.
48 results